Adding tucidinostat to standard chemo for double-expressor lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial compares two treatments for a certain type of aggressive lymphoma: the standard R-CHOP chemotherapy plus a study drug called tucidinostat (which may help fight cancer cells). The aim is to see if adding this drug helps patients with the double-expressor subtype do better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have been diagnosed with a type of lymphoma called diffuse large B-cell lymphoma (a cancer of the immune system).
- You have not had any chemotherapy, immunotherapy, or other treatment for this disease yet.
- Your lymphoma cells have high levels of two specific proteins (MYC and BCL-2), but not the genetic rearrangements that make it a double-hit lymphoma.
- You have at least one visible tumor on a PET/CT scan.
- Your cancer is considered intermediate or high risk based on a scoring system (IPI score of 2 to 4).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different drug combinations to see which is better for people with a type of lymphoma that has certain genetic markers. It aims to improve outcomes for patients who have not received treatment before.
This trial tests a new sequence of two chemotherapy regimens (RLC followed by CR-CHOP) for elderly patients with a fast-growing DLBCL called double expressor lymphoma. The goal is to see if this approach is safe and effective for people who may not tolerate standard treatments.
This trial tests whether adding a new targeted drug called birelentinib to the standard chemotherapy combination (R-CHOP) helps people with newly diagnosed aggressive lymphoma. It aims to improve the chances of remission and reduce the risk of the lymphoma coming back.
This study tests a new drug (TRS005) combined with standard chemotherapy (cyclophosphamide, doxorubicin, and prednisone) as a first treatment for people with CD20-positive DLBCL. The goal is to see if this combination is safe and effective in controlling the lymphoma.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
This trial tests a treatment plan that includes the drug tucidinostat for people who have not yet been treated for a type of lymphoma called DLBCL. It focuses on patients whose cancer cells have certain features (double expression of MYC and BCL2, or certain gene changes) that might affect how well standard treatments work.
Hear when a new Double Expressor Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.